$30.1 M

BPMX Mkt cap, 04-Dec-2018

$10 K

BioPharmX Revenue Q3, 2019
BioPharmX Gross profit (Q3, 2019)-50 K
BioPharmX Gross profit margin (Q3, 2019), %(500%)
BioPharmX EBIT (Q3, 2019)-4.5 M
BioPharmX Cash, 31-Oct-20183 M

BioPharmX Income Statement

BioPharmX Balance Sheet

Annual

USDFY, 2013FY, 2016FY, 2017FY, 2018

Cash

162.04.0m6.5m7.6m

Accounts Receivable

7.0k4.0k7.0k

Inventories

100.0k38.0k10.0k

Current Assets

39.0k4.4m6.8m8.0m

PP&E

32.0k216.0k120.0k109.0k

Total Assets

162.04.9m7.1m8.1m

Accounts Payable

491.0k1.8m2.6m1.4m

Current Liabilities

120.1k2.8m3.7m3.0m

Long-term debt

938.0k

Total Debt

938.0k

Total Liabilities

123.1k4.1m3.0m

Additional Paid-in Capital

13.0k28.3m46.0m66.2m

Retained Earnings

(26.2m)(44.6m)(61.3m)

Total Equity

(1.4m)2.1m3.0m5.1m

Debt to Equity Ratio

-0.7 x

Debt to Assets Ratio

5.8 k x

Financial Leverage

0 x2.4 x2.4 x1.6 x

BioPharmX Cash Flow

Annual

USDFY, 2013FY, 2016FY, 2017FY, 2018

Net Income

(52.3k)(15.6m)(18.4m)(16.6m)

Depreciation and Amortization

207.056.0k141.0k52.0k

Accounts Receivable

(6.0k)3.0k(3.0k)

Inventories

60.0k62.0k28.0k

Accounts Payable

446.0k625.0k774.0k(1.2m)

Cash From Operating Activities

(7.4k)(12.6m)(15.7m)(15.6m)

Purchases of PP&E

(25.0k)(38.0k)(45.0k)(41.0k)

Cash From Investing Activities

(85.0k)(38.0k)(45.0k)(41.0k)

Cash From Financing Activities

2.9k15.4m18.3m16.7m

Income Taxes Paid

4.0k2.0k2.0k

BioPharmX Ratios

USDY, 2018

Financial Leverage

6.3 x
Report incorrect company information